Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium.
Sympathetic nerves have long been suspected of trophic activity, but the nature of their angiogenic factor has not been determined. Neuropeptide Y (NPY), a sympathetic cotransmitter, is the most abundant peptide in the heart and the brain. It is released during nerve activation and ischemia and causes vasoconstriction and smooth muscle cell proliferation. Here we report the first evidence that NPY is angiogenic. At low physiological concentrations, in vitro, it promotes vessel sprouting and adhesion, migration, proliferation, and capillary tube formation by human endothelial cells. In vivo, in a murine angiogenic assay, NPY is angiogenic and is as potent as a basic fibroblast growth factor. The NPY action is specific and is mediated by Y1 and Y2 receptors. The expression of both receptors is upregulated during cell growth; however, Y2 appears to be the main NPY angiogenic receptor. Its upregulation parallels the NPY-induced capillary tube formation on reconstituted basement membrane (Matrigel); the Y2 agonist mimics the tube-forming activity of NPY, whereas the Y2 antagonist blocks it. Endothelium contains not only NPY receptors but also peptide itself, its mRNA, and the "NPY-converting enzyme" dipeptidyl peptidase IV (both protein and mRNA), which terminates the Y1 activity of NPY and cleaves the Tyr1-Pro2 from NPY to form an angiogenic Y2 agonist, NPY3-36. Endothelium is thus not only the site of action of NPY but also the origin of the autocrine NPY system, which, together with the sympathetic nerves, may be important in angiogenesis during tissue development and repair.
Zukowska-Grojec
Z
Z
Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC 20007, USA. zzukow01@medlib.georgetown.edu
Karwatowska-Prokopczuk
E
E
Rose
W
W
Rone
J
J
Movafagh
S
S
Ji
H
H
Yeh
Y
Y
Chen
W T
WT
Kleinman
H K
HK
Grouzmann
E
E
Grant
D S
DS
D000818:Animals; D001011:Aorta / Q000187:drug effects; D002196:Capillaries; D003094:Collagen / Q000494:pharmacology; D018819:Dipeptidyl Peptidase 4 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology; D004338:Drug Combinations; D016228:Endothelial Growth Factors / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000737:chemistry*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D015870:Gene Expression; D006801:Humans; D007797:Laminin / Q000494:pharmacology; D008222:Lymphokines / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009478:Neuropeptide Y / Q000096:biosynthesis / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D010446:Peptide Fragments / Q000378:metabolism / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D011509:Proteoglycans / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D017476:Receptors, Neuropeptide Y / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D013564:Sympathetic Nervous System / Q000737:chemistry*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D004338:Drug Combinations; D016228:Endothelial Growth Factors; D007797:Laminin; D008222:Lymphokines; D009478:Neuropeptide Y; D010446:Peptide Fragments; D011509:Proteoglycans; D012333:RNA, Messenger; D017476:Receptors, Neuropeptide Y; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C113547:neuropeptide Y (3-36); C095889:neuropeptide Y2 receptor; D016222:Fibroblast Growth Factor 2; C059485:matrigel; D003094:Collagen; D018819:Dipeptidyl Peptidase 4